Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

Blue light treatment kills food poisoning bacteria on raw chicken

A low-power blue light could be the key to significantly reducing food poisoning caused by raw chicken in the UK, scientists at the University of Reading have found.

6 Oct 2026

Weekly cisplatin fails to reduce acute toxicity in advanced head and neck cancer

Physicians typically use either a higher dose of cisplatin given every three weeks or a lower dose given weekly in combination with radiation to treat locally advanced head and neck cancer.

29 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

Veterinary sedative in fentanyl supply spikes severe withdrawal cases

A powerful veterinary sedative, medetomidine, is increasingly infiltrating the street supplies of the already deadly opioid fentanyl, with patients suffering from its withdrawal quadrupling in recent years, according to a new analysis by researchers at the Perelman School of Medicine at the University of Pennsylvania.

29 Sep 2026

Nasal spray offers needle-free pain relief for children with injuries

A treatment for pain, that is delivered via a nasal spray, offers an effective, needle-free option for children being seen in the emergency department for a range of injuries, according to research presented at the European Emergency Medicine Congress today (Sunday).

27 Sep 2026

Common anti-epileptic medication shows promise in reducing migraine aura

A new study by researchers at Lund University in Sweden found that 85 percent of patients with aura-dominant migraine experienced a reduction in monthly aura days by at least half following treatment with the anti-epileptic drug lamotrigine.

25 Sep 2026

A 30-day benznidazole regimen offers safer Chagas disease treatment option

A 30-day course of benznidazole taken once a day could offer people with chronic Trypanosoma cruzi infection a safer and more practical option than the current standard treatment, taken twice a day for 60 days.

22 Sep 2026

Mifepristone offers effective emergency contraception with fewer side effects

Emergency contraception containing mifepristone prevents more pregnancies with fewer side effects than some other common emergency contraceptive pills such as levonorgestrel, according to a new Cochrane review involving 87 trials.

20 Sep 2026

Women with hyperemesis gravidarum report major gaps in care

Medical assistance can help women suffering from severe nausea and vomiting during pregnancy, but insufficient recognition of Hyperemesis gravidarum (HG) means that many are not getting the help they need to overcome this severe and debilitating form of morning sickness.

17 Sep 2026

Sacituzumab govitecan combination misses progression-free survival endpoint in metastatic NSCLC

Sacituzumab govitecan (SG) plus pembrolizumab did not demonstrate a statistically significant improvement in progression-free survival compared with pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) and PD-L1 tumor proportion score (TPS) of 50% or greater, according to primary results from the Phase 3 EVOKE-03/KEYNOTE-D46 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

15 Sep 2026

AI identifies hidden biological patterns to accurately diagnose migraines

AI can trawl vast amounts of health data which is not specifically related to migraines, but which can be used to identify people predisposed to the condition.

11 Sep 2026

Daraxonrasib shows durable responses in RAS-mutant lung cancer

Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.

2 Sep 2026

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence for GLP-1 microdosing remains extremely limited, and researchers say prospective studies are needed to determine whether lower doses preserve long-term benefits.

1 Sep 2026

New guideline updates medications for preventing migraine in adults

To help clinicians determine which medications may be most effective at preventing migraine in adults, the American Academy of Neurology (AAN) and American Headache Society (AHS) have issued a joint practice guideline update with evidence-based recommendations, published on August 31, 2026, in Neurology®, the medical journal of the American Academy of Neurology, and in Headache, the official journal of the American Headache Society.

31 Aug 2026

Breastmilk from cannabis users showed differences, but cannabis may not be the whole story

A narrative review found that maternal cannabis use may be associated with differences in breastmilk fat, protein, lactose, and the immune factor secretory immunoglobulin A, but evidence comes primarily from only two human studies and remains limited and inconsistent. The authors stress that maternal diet, food security, socioeconomic circumstances, and other forms of adversity could confound these associations and should be incorporated into future research.

31 Aug 2026

A personalized elimination diet changed the gut microbiome in people with migraine

In a 12-week randomized, sham-controlled trial of 98 adults with migraine, eliminating IgG-positive foods altered gut microbial composition and produced a greater reduction in serum zonulin than a sham elimination diet. The microbial changes were associated with previously reported reductions in CGRP and IL-6 and improvements in migraine and sleep, although the authors emphasized that these mechanistic links remain exploratory.

31 Aug 2026

Experts call for safer weight loss as concerns grow over GLP-1 use

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe, nutritionally adequate, and properly supervised. Drawing on Japanese reports of ketosis and ketoacidosis following inappropriate tirzepatide use, the authors call for greater attention to the risks of unsafe weight-loss practices alongside medication-related harms.

30 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026